Monoclonal antibodies and other biologic agents in the treatment of asthma

Long, Aidan A.

doi:10.4161/mabs.1.3.8352

Cited by 23 publications

(19 citation statements)

References 101 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…TNF alpha is mainly secreted by monocytes and macrophages [34] . But under certain circumstances, TNF alpha can also be secreted by endothelial cells, vascular smooth muscle cells, and cardiac fibroblast cells [35] . TNF alpha could damage endothelial cells and vessel wall, and thus contribute to the formation of plaques [36] , possibly through stimulating the synthesis of matrix metalloproteinases 9 (MMP 9) by mac rophage [37,38] .…”

Section: Discussionmentioning

confidence: 99%

Danshensu protects vascular endothelia in a rat model of hyperhomocysteinemia

et al. 2010

View full text Add to dashboard Cite

Aim: To examine whether danshensu could protect vascular endothelia in a rat model of hyperhomocysteinemia. Methods: The model was established by feeding rats with a methionine-rich diet (1 g·kg -1 ·d -1 ) for 3 months. Immediately following the discontinuation of methionine-rich diet, rats were treated with danshensu (67.5 mg·kg -1 ·d -1 , po) or saline for 3 additional months. One group of rats receiving vitamin mixture (folic acid, vitamin B12 and vitamin B6) was included as a positive control. One group of rats not exposed to methionine-rich diet was also included as a blank control. The expression of tumor necrosis factor-alpha (TNF-alpha) and intercellular adhesion molecule-1 (ICAM-1) protein in the descending aorta was examined using immunohistochemistry and Western blot. Homocysteine and blood concentration of endothelin and nitric oxide (NO) was also examined. Results: Methionine-rich diet resulted in accumulation of "foam cells", up-regulated expression of TNF-alpha and ICAM-1 in the descending aorta, and significantly increased serum homocysteine. Plasma endothelin concentration was significantly increased; NO was decreased. Danshensu treatment, either simultaneous to methionine-rich diet or afterwards, attenuated the above mentioned changes. Conclusion: Chronic treatment with danshensu could prevent/attenuate the formation of atherosclerosis. Potential mechanisms include inhibited expression of representative proinflammatory cytokines and adhesion molecules in arterial endothelia. Changes in homocysteine and circulating molecules that control vascular contraction/relaxation via endothelial cells (eg, endothelin and NO) were also implicated.

show abstract

Section: Discussionmentioning

confidence: 99%

Danshensu protects vascular endothelia in a rat model of hyperhomocysteinemia

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Побочных реакций на введение пасколизумаба не регистрировалось, однако прием препарата не оказывал существенного влияния на улучшение со стояния больных. В настоящее время исследование пасколизумаба приостановлено [32].…”

Section: Mkoike Et Al апробировали рекомбинантные гумаunclassified

Bronchial asthma: novel therapeutic approaches

Чучалин¹

2011

Pulʹmonologiâ (Mosk.)

View full text Add to dashboard Cite

“…Further development of pascolizumab was discontinued [Long, 2009b]. There were no significant adverse reactions reported.…”

Section: Pascolizumabmentioning

confidence: 99%

“…This was initially discussed by Brightbill and colleagues who generated mAb against the M1' segment of human IgE through the immunization of mice but more investigation will be required to assess this possible approach [Brightbill et al 2010]. Additional opportunities for therapy may include anti-CD69 mAb [Miki-Hosokawa et al 2009], targeting IL-25 [Long, 2009b], using agents that target intracellular adhesion molecules, and possibly therapies that directly act against mast cells and their mediators [Singh and Kraft, 2008].…”

Section: Amg-317mentioning

confidence: 99%

The role of monoclonal antibodies in the treatment of severe asthma

Tourangeau

Kavanaugh²,

Wasserman

2011

Ther Adv Respir Dis

View full text Add to dashboard Cite

A number of therapeutic agents are available for the treatment of asthma, including inhaled corticosteroids, long-and short-acting beta-agonists, leukotriene-modifying agents, long-and short-acting anticholinergic agents, chromones, theophylline, allergen immunotherapy, and oral corticosteroid therapy. All available therapies, despite their proven efficacy, are purely symptomatic including the topical steroids. This issue has led to the development of several biologic agents to aid in asthma management and to potentially alter the course of the disease by interfering with specific aspects of inflammation which may modify remodeling in the airways. Monoclonal antibodies have offered a class of therapeutic agents that enhance treatment options for patients with moderate-to-severe persistent asthma. As such, this article provides an overview of present and future monoclonal antibody therapies for the treatment of patients with severe asthma.

show abstract

Monoclonal antibodies and other biologic agents in the treatment of asthma

Cited by 23 publications

References 101 publications

Danshensu protects vascular endothelia in a rat model of hyperhomocysteinemia

Danshensu protects vascular endothelia in a rat model of hyperhomocysteinemia

Bronchial asthma: novel therapeutic approaches

The role of monoclonal antibodies in the treatment of severe asthma

Contact Info

Product

Resources

About